Because of the PI3K/AKT/mTOR pathway involvement in KRAS downstream signalling, and given the synergy of this association in cancer cell lines harbouring various subtypes of KRAS mutations, VS-6766 is also being evaluated in combination with the mTOR complex1 (mTORC1) inhibitor everolimus in a phase I study (NCT02407509). The gene discussed is KRAS; the disease is cancer.